Research programme: calpain/proteasome inhibitors - Santhera Pharmaceuticals
Alternative Names: SNT 197958; SNT 198174; SNT 198337Latest Information Update: 16 Mar 2009
At a glance
- Originator Santhera Pharmaceuticals
- Class Dipeptides
- Mechanism of Action Calpain inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cataracts; Muscular atrophy; Muscular dystrophies
Most Recent Events
- 16 Mar 2009 Discontinued - Preclinical for Cataracts in Switzerland (unspecified route)
- 16 Mar 2009 Discontinued - Preclinical for Muscle wasting in Switzerland (unspecified route)
- 16 Mar 2009 Discontinued - Preclinical for Muscular dystrophies in Switzerland (unspecified route)